Lumos Pharma, Inc.

Equities

LUMO

US55028X1090

Biotechnology & Medical Research

Delayed Nasdaq Other stock markets 13:30:00 2024-07-03 EDT			5-day change	1st Jan Change
2.2 ^USD	-3.08%		-2.44%	-30.82%

06-04	Lumos Pharma, Inc. Announces New Analyses of Phase 2 OraGrowtH212 Trial Presented at ENDO 2024	CI
05-15	Lumos Pharma Announces Positive End-of-Phase 2 Meeting with FDA	CI

Newlink Genetics Corporation to Present Phase 1b Data on Indoximod in Combination Therapy in Patients with Metastatic Pancreatic Cancer at ASCO GI

January 19, 2016 at 05:00 pm

NewLink Genetics Corporation announced that it will present Phase 1b data from a Phase 1/2 trial that examines combination therapy of indoximod plus gemcitabine/nab-paclitaxel in treating patients with metastatic pancreatic cancer at the 2016 Gastrointestinal Cancers Symposium (ASCO GI) in San Francisco.

Latest news about Lumos Pharma, Inc.

Lumos Pharma, Inc. Announces New Analyses of Phase 2 OraGrowtH212 Trial Presented at ENDO 2024	06-04	CI
Lumos Pharma Announces Positive End-of-Phase 2 Meeting with FDA	05-15	CI
Lumos Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-15	CI
Transcript : Lumos Pharma, Inc., Q1 2024 Earnings Call, May 15, 2024	05-15
Lumos Pharma Plans Phase 3 Study of Growth Hormone Drug	05-14	MT
Earnings Flash (LUMO) LUMOS PHARMA Posts Q1 Revenue $165,000, vs. Street Est of $0.3M	05-14	MT
Lumos Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-07	CI
Transcript : Lumos Pharma, Inc., 2023 Earnings Call, Mar 07, 2024	03-07
Earnings Flash (LUMO) LUMOS PHARMA Reports Q4 Revenue $2.1M	03-07	MT
Lumos Pharma, Inc. Promotes Pisit Pitukcheewanont to Chief Medical Officer	01-04	CI
Oppenheimer Trims Lumos Pharma Price Target to $16 From $17, Maintains Outperform Rating	12-11	MT
Transcript : Lumos Pharma, Inc. - Special Call	12-06
North American Morning Briefing : Stock Futures -2-	11-13	DJ
Transcript : Lumos Pharma, Inc. - Special Call	11-08
Top Premarket Gainers	11-08	MT
Lumos Pharma Phase 2 Trials Targeting Pediatric Growth Hormone Deficiency Meet Endpoints; Shares Surge Premarket	11-08	MT
Lumos Pharma Shares Than Double After Hormone Deficiency Trial Meets All Endpoints	11-07	DJ
Tranche Update on Lumos Pharma, Inc.'s Equity Buyback Plan announced on August 16, 2022.	11-07	CI
Lumos Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-07	CI
Earnings Flash (LUMO) LUMOS PHARMA Posts Q3 Revenue $7,000	11-07	MT
Lumos Pharma, Inc. Announces Topline Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials of LUM-201 inPGHD Met All Primary and Secondary Endpoints	11-07	CI
Lumos Pharma Says New Data Shows LUM-201 Restored Growth Hormone Secretion to Similar Levels in Normally Growing Children	23-09-26	MT
Lumos Pharma Announces New Data and Analysis of 15 Subjects from Oragrowth212 Trial Presented At the 2023 ESPE Annual Meeting	23-09-26	CI
Lumos Pharma, Inc. Announces Abstract Accepted for Oral Presentation at the European Society for Paediatric Endocrinology Annual Meeting	23-09-14	CI
Transcript : Lumos Pharma, Inc. - Special Call	23-09-05

Chart Lumos Pharma, Inc.

Duration

Period

More charts

Company Profile

Lumos Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in advancing its clinical program and focused on identifying, acquiring, developing, and commercializing products and new therapies for people with rare diseases. Its pipeline is focused on the development of an orally administered small molecule, LUM-201, which is a growth hormone (GH) secretagogue, also called ibutamoren, for rare endocrine disorders that require injectable recombinant human growth hormone (rhGH). LUM-201 is a tablet formulation that is intended to be administered once daily. LUM-201 stimulates GH via the GH secretagogue receptor (GHSR1a), also known as the ghrelin receptor, and also suppresses the release of somatostatin, thus providing a differentiated mechanism of action to treat some rare endocrine disorders (involving a deficiency of GH) by increasing the amplitude of endogenous, pulsatile GH secretion. Lumos Pharma Sub, Inc. (Private Lumos) is its subsidiary.

Sector

Biotechnology & Medical Research

Calendar

2024-11-11 - Q3 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Lumos Pharma, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.27 USD

Average target price

22.5 USD

Spread / Average Target

+891.19%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
LUMOS PHARMA, INC.	-30.82%	18.42M
MODERNA, INC.	+16.59%	44.87B
IQVIA HOLDINGS INC.	-10.62%	37.8B
LONZA GROUP AG	+40.49%	37.61B
ALNYLAM PHARMACEUTICALS, INC.	+29.92%	31.32B
CELLTRION, INC.	-9.78%	27.4B
ICON PUBLIC LIMITED COMPANY	+12.34%	26.32B
UNITED THERAPEUTICS CORPORATION	+41.53%	14.07B
MEDPACE HOLDINGS, INC.	+31.49%	12.5B
BIO-TECHNE CORPORATION	-7.40%	11.23B

Other Biotechnology & Medical Research